129 related articles for article (PubMed ID: 20145160)
1. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.
Hammarsten P; Karalija A; Josefsson A; Rudolfsson SH; Wikström P; Egevad L; Granfors T; Stattin P; Bergh A
Clin Cancer Res; 2010 Feb; 16(4):1245-55. PubMed ID: 20145160
[TBL] [Abstract][Full Text] [Related]
2. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer.
Chung SC; Hammarsten P; Josefsson A; Stattin P; Granfors T; Egevad L; Mancini G; Lutz B; Bergh A; Fowler CJ
Eur J Cancer; 2009 Jan; 45(1):174-82. PubMed ID: 19056257
[TBL] [Abstract][Full Text] [Related]
3. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.
Noordhuis MG; Eijsink JJ; Ten Hoor KA; Roossink F; Hollema H; Arts HJ; Pras E; Maduro JH; Reyners AK; de Bock GH; Wisman GB; Schuuring E; van der Zee AG
Clin Cancer Res; 2009 Dec; 15(23):7389-97. PubMed ID: 19920104
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade.
Liao Y; Abel U; Grobholz R; Hermani A; Trojan L; Angel P; Mayer D
Hum Pathol; 2005 Nov; 36(11):1186-96. PubMed ID: 16260272
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
6. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
7. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting.
Borre M; Nerstrøm B; Overgaard J
Clin Cancer Res; 2000 May; 6(5):1882-90. PubMed ID: 10815911
[TBL] [Abstract][Full Text] [Related]
8. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.
Egevad L; Granfors T; Karlberg L; Bergh A; Stattin P
J Urol; 2002 Aug; 168(2):509-13. PubMed ID: 12131299
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly.
Borre M; Bentzen SM; Nerstrøm B; Overgaard J
J Urol; 1998 May; 159(5):1609-14. PubMed ID: 9554364
[TBL] [Abstract][Full Text] [Related]
10. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
11. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.
Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Horsfall DJ
Clin Cancer Res; 1998 Apr; 4(4):963-71. PubMed ID: 9563891
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
16. A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.
Donovan MJ; Khan FM; Bayer-Zubek V; Powell D; Costa J; Cordon-Cardo C
BJU Int; 2012 Jan; 109(2):207-13. PubMed ID: 21733075
[TBL] [Abstract][Full Text] [Related]
17. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
18. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma.
Hoshino M; Fukui H; Ono Y; Sekikawa A; Ichikawa K; Tomita S; Imai Y; Imura J; Hiraishi H; Fujimori T
Pathobiology; 2007; 74(1):15-21. PubMed ID: 17496429
[TBL] [Abstract][Full Text] [Related]
19. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer.
Stattin P; Damber JE; Karlberg L; Bergh A
J Urol; 1997 Jan; 157(1):219-22. PubMed ID: 8976256
[TBL] [Abstract][Full Text] [Related]
20. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
